Unknown PHASE2 INTERVENTIONAL 2-arm NCT04963595

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Phase II Study of Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Sponsor: Zhiyong Yu

Conditions Metastatic Breast Cancer

Interventions Inetetamab Pyrotinib Vinorelbine

Updated 3 times since 2021 Last updated: Jul 11, 2021 Started: Aug 1, 2021 Primary completion: Jan 31, 2023 Completion: Jul 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04963595, this PHASE2 trial focuses on Metastatic Breast Cancer and remains ongoing. Sponsored by Zhiyong Yu, it has been updated 3 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhiyong Yu

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.